OncoMatch/Clinical Trials/NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Official title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Is NCT05519085 recruiting? Yes, currently enrolling (Oct 2026). This Phase 3 trial studies multiple treatments including mezigdomide and Pomalidomide for relapsed or refractory multiple myeloma.
Treatment: mezigdomide · Pomalidomide · Bortezomib · Dexamethasone — The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Endocrine / hormonal
Other
Cancer type
Multiple Myeloma
Prior therapy
Must have received: antimyeloma therapy
Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.
Cannot have received: proteasome inhibitor
Exception: Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks (or less frequently) are not excluded. Participants who progressed while being treated with ixazomib monotherapy maintenance ≥ 6 months prior to the time of starting study treatment are not excluded.
Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below
Cannot have received: bortezomib-containing regimen (bortezomib)
For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
Cannot have received: (mezigdomide, pomalidomide)
Participant has had prior treatment with mezigdomide or pomalidomide.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cancer and Blood Specialty Clinic · Los Alamitos, California
- Sharp Memorial Hospital · San Diego, California
- Local Institution - 0273 · West Hollywood, California
- Local Institution - 0381 · Aurora, Colorado
- UConn Health · Farmington, Connecticut
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05519085 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior proteasome inhibitor, bortezomib-containing regimen, disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages